{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:11:32Z","timestamp":1789668692923,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1245\/s10434-026-20338-4","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:30:48Z","timestamp":1786462248000},"page":"9307-9316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune-Adjusted Nodal Risk Classification After Neoadjuvant Immunotherapy for Resectable Head and Neck Cutaneous Squamous Cell Carcinoma"],"prefix":"10.1245","volume":"33","author":[{"given":"Yajing","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongqiong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"20338_CR1","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-21-0585","volume":"27","author":"R Ferrarotto","year":"2021","unstructured":"Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, et al. Pilot Phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2021;27:4557\u201365.","journal-title":"Clin Cancer Res."},{"key":"20338_CR2","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","volume":"387","author":"ND Gross","year":"2022","unstructured":"Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, et al. Neoadjuvant Cemiplimab for stage II to IV cutaneous squamous cell carcinoma. N Engl J Med. 2022;387:1557\u201368.","journal-title":"N Engl J Med."},{"key":"20338_CR3","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S1470-2045(23)00459-X","volume":"24","author":"ND Gross","year":"2023","unstructured":"Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, et al. Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. Lancet Oncol. 2023;24:1196\u2013205.","journal-title":"Lancet Oncol."},{"key":"20338_CR4","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/jamaoto.2023.1729","volume":"149","author":"R Ferrarotto","year":"2023","unstructured":"Ferrarotto R, Nagarajan P, Maronge JM, Johnson JM, Rosenthal DI, Myers JN, et al. Outcomes of treatment with neoadjuvant cemiplimab for patients with advanced, resectable cutaneous squamous cell carcinoma of the head and neck: secondary analysis of a phase 2 clinical trial. JAMA Otolaryngol Head Neck Surg. 2023;149:847\u20139.","journal-title":"JAMA Otolaryngol Head Neck Surg."},{"key":"20338_CR5","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1001\/jamaoto.2024.0259","volume":"150","author":"EY Kim","year":"2024","unstructured":"Kim EY, Ruiz ES, DeSimone MS, Shalhout SZ, Hanna GJ, Miller DM, Schmults C, Rettig EM, Foreman RK, Sethi R, Thakuria M, Silk AW. Neoadjuvant-intent immunotherapy in advanced, resectable cutaneous squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2024;150:414\u201320.","journal-title":"JAMA Otolaryngol Head Neck Surg."},{"key":"20338_CR6","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.3390\/cancers17101727","volume":"17","author":"AM Lim","year":"2025","unstructured":"Lim AM, Baker B, Lion P, Angel CM, Simmons J, Jackson B, et al. Radiological, pathological, and surgical outcomes with neoadjuvant Cemiplimab for stage II-IV cutaneous squamous cell carcinoma in the deep sequencing in cutaneous squamous cell carcinomas (DISCERN) trial. Cancers (Basel). 2025;17:1727.","journal-title":"Cancers (Basel)."},{"key":"20338_CR7","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1001\/jamaoto.2024.3103","volume":"150","author":"A Ebrahimi","year":"2024","unstructured":"Ebrahimi A, Gupta R, McDowell L, Magarey MJR, Smith PN, Schulte KM, et al. Determinants of prognosis in head and neck cutaneous squamous cell carcinoma with nodal metastases. JAMA Otolaryngol Head Neck Surg. 2024;150:986\u201394.","journal-title":"JAMA Otolaryngol Head Neck Surg."},{"key":"20338_CR8","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1186\/s12885-024-12384-6","volume":"24","author":"Q Fang","year":"2024","unstructured":"Fang Q, Yuan J, Zhang X, Dai L, Luo R. Lymph node metastasis in cutaneous squamous cell carcinoma of the head and neck. BMC Cancer. 2024;24:656.","journal-title":"BMC Cancer."},{"key":"20338_CR9","doi-asserted-by":"publisher","first-page":"7348","DOI":"10.1038\/s41467-021-26472-9","volume":"12","author":"JL Vos","year":"2021","unstructured":"Vos JL, Elbers JBW, Krijgsman O, Traets JJH, Qiao X, van der Leun AM, et al. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nat Commun. 2021;12:7348.","journal-title":"Nat Commun."},{"key":"20338_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/ajd.13739","volume":"63","author":"NW Bucknell","year":"2022","unstructured":"Bucknell NW, Gyorki DE, Bressel M, Estall V, Webb A, Henderson M, et al. Cutaneous squamous cell carcinoma metastatic to the axilla and groin: outcomes and prognostic factors. Australas J Dermatol. 2022;63:43\u201352.","journal-title":"Australas J Dermatol."},{"key":"20338_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.545433","volume":"11","author":"P Li","year":"2021","unstructured":"Li P, Fang Q, Yang Y, Chen D, Du W, Liu F, Luo R. Survival significance of number of positive lymph nodes in oral squamous cell carcinoma stratified by p16. Front Oncol. 2021;11:545433.","journal-title":"Front Oncol."},{"key":"20338_CR12","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1002\/hed.27676","volume":"46","author":"Q Fang","year":"2024","unstructured":"Fang Q, Yuan J, Zhang X, Dai L, Luo R, Xu C. Neck management in cutaneous squamous cell carcinoma with parotid metastasis. Head Neck. 2024;46:1938\u201345.","journal-title":"Head Neck."},{"key":"20338_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/jmrs.650","volume":"70","author":"M Hu","year":"2023","unstructured":"Hu M, Kim ANH, Emeto TI, Collins M, Chopping A, Lin C. Metastatic cutaneous squamous cell carcinoma to the parotid: adjuvant radiotherapy and treatment outcomes. J Med Radiat Sci. 2023;70:161\u201370.","journal-title":"J Med Radiat Sci."},{"key":"20338_CR14","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1001\/jamaoto.2025.2110","volume":"151","author":"SV Porceddu","year":"2025","unstructured":"Porceddu SV, Connolly E, Bressel M, Wratten C, Liu HY, Rischin D. Prognostic subgroups for disease-free survival with cutaneous squamous cell carcinoma of the head and neck: a secondary analysis of a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2025;151:938\u201345.","journal-title":"JAMA Otolaryngol Head Neck Surg."},{"key":"20338_CR15","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/lary.30158","volume":"133","author":"K Joshi","year":"2023","unstructured":"Joshi K, Agarwal M, Pasricha S, Singh A, Garg S, Rai S, Tandon S. Macroscopic extranodal extension in oral squamous cell carcinoma: a subgroup with poor Survival. Laryngoscope. 2023;133:588\u201393.","journal-title":"Laryngoscope."},{"key":"20338_CR16","volume":"6","author":"L Gonz\u00e1lez-Vallejo","year":"2023","unstructured":"Gonz\u00e1lez-Vallejo L, Blanco-Sainzdelamaza J, Querejeta-Ayerra A, Chiesa-Estomba C. Extracapsular nodal extension and tumor deposits in head and neck squamous cell carcinoma. Cancer Rep (Hoboken). 2023;6:e1897.","journal-title":"Cancer Rep (Hoboken)."},{"key":"20338_CR17","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41379-021-00777-y","volume":"34","author":"P Zens","year":"2021","unstructured":"Zens P, Bello C, Scherz A, Koenigsdorf J, P\u00f6llinger A, Schmid RA, et al. A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response. Mod Pathol. 2021;34:1333\u201344.","journal-title":"Mod Pathol."},{"key":"20338_CR18","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","volume":"28","author":"TM Wise-Draper","year":"2022","unstructured":"Wise-Draper TM, Gulati S, Palackdharry S, Hinrichs BH, Worden FP, Old MO, et al. Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma. Clin Cancer Res. 2022;28:1345\u201352.","journal-title":"Clin Cancer Res."},{"key":"20338_CR19","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-22-0666","volume":"28","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Wu B, Peng G, Xiao G, Huang J, Ding Q, et al. Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: a single-arm phase 2 clinical trial. Clin Cancer Res. 2022;28:3268\u201376.","journal-title":"Clin Cancer Res."},{"key":"20338_CR20","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.1038\/s41467-022-33080-8","volume":"13","author":"WT Ju","year":"2022","unstructured":"Ju WT, Xia RH, Zhu DW, Dou SJ, Zhu GP, Dong MJ, et al. A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma. Nat Commun. 2022;13:5378.","journal-title":"Nat Commun."},{"key":"20338_CR21","doi-asserted-by":"publisher","first-page":"1282629","DOI":"10.3389\/fimmu.2023.1282629","volume":"14","author":"WJ Wu","year":"2023","unstructured":"Wu WJ, Liu Q, An PG, Wang L, Zhang JY, Chen Y, et al. Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real-world retrospective study. Front Immunol. 2023;14:1282629.","journal-title":"Front Immunol."},{"key":"20338_CR22","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1056\/NEJMoa2502449","volume":"393","author":"D Rischin","year":"2025","unstructured":"Rischin D, Porceddu S, Day F, Brungs DP, Christie H, Jackson JE, et al. C-POST trial Investigators, adjuvant Cemiplimab or placebo in high-risk cutaneous squamous-cell carcinoma. N Engl J Med. 2025;393:774\u201385.","journal-title":"N Engl J Med."},{"key":"20338_CR23","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1002\/hed.26835","volume":"43","author":"PJ Kreinbrink","year":"2021","unstructured":"Kreinbrink PJ, Mierzwa ML, Huth B, Redmond KP, Wise-Draper TM, Casper K, Li J, Takiar V. Adjuvant radiation and cetuximab improves local control in head and neck cutaneous squamous cell carcinoma: Phase II study. Head Neck. 2021;43:3408\u201316.","journal-title":"Head Neck."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20338-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20338-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20338-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:52:47Z","timestamp":1789667567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20338-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20338"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20338-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"22 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None declared.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study protocol was approved by the Ethics Committee of The First Affiliated Hospital of Zhengzhou University. Written informed consent was obtained from each patient at initial treatment. All methods were performed in accordance with the Declaration of Helsinki.","order":4,"name":"Ethics","label":"Ethical Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}